Clinical trials: Overactive Detrusor
Bladder Disorder, Neurogenic
Heart Rate Variability (HRV) in Patients With Neurogenic Detrusor Overactivity (NDO) Before and After Botulinum Neurotoxin Type A (BoNT/A) Intradetrusor Injections
Heart rate variability (HRV) is an important indicator of cardiac autonomic function and predictor of cardiac mortality and of all-cause mortality.
- Trial name
- HRV/Botox (NCT01337024)
- Where
- Switzerland
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Balgrist University Hospital
Benign Prostatic Hypertrophy With Outflow Obstruction, Overactive Detrusor
Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia
Persistent detrusor overactivity (DO) after transurethral prostatectomy results in symptomatic failure in more than one third of the patients.
- Trial name
- NCT01781117
- Testing
- Holmium Laser Enucleation of the Prostate (HoLEP), Holmium laser enucleation system and morcellator
- Where
- South Korea
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- KYU-SUNG LEE
Bladder Outlet Obstruction
An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia
The subjects who have symptoms of overactive bladder (many trips to the bathroom, and urgency with or without the inability to hold your urine until you get to the toilet) are invited to participate in this research study.
- Trial name
- Toviaz (NCT00605319)
- Testing
- Toviaz (Fesoterodine)
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Spinal Cord Injury, Neurogenic Detrusor Overactivity
Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury?
Spinal cord injury (SCI) almost always affects bladder function as well. As a result of this bladder dysfunction, individuals with SCI have to undergo regular invasive examination of their bladder function (urodynamic…
- Conditions
- Spinal Cord Injury, Neurogenic Detrusor Overactivity, Neurogenic Lower Urinary Tract Dysfunction
- Trial name
- NCT02138149
- Where
- Switzerland
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Swiss Paraplegic Research, Nottwil
Detrusor Overactivity
Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity
In the last decade, several authors proposed ultrasound measurement of Bladder wall thickness (BWT) for the screening of the voiding dysfunction and of the detrusor overactivity (DO).
- Trial name
- NCT01003457
- Testing
- ultrasonography
- Where
- Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Università degli Studi dell'Insubria
Neurogenic Detrusor Overactivity
Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer
Open Label, Single-Dose, Crossover Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule (BIC) SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled…
- Trial name
- NCT04452838
- Testing
- Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B), Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B), Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)
- Where
- Belgium
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pfizer
Detrusor Overactivity
UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation
The purpose of this study is to find a noninvasive test to help physicians diagnose detrusor overactivity (DO), to use this urine test to help diagnose bladder problems, determine if treatments are working, and determine if…
- Trial name
- NCT01850706
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Overactive Bladder
Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity
The purpose of this study is to evaluate the safety of a new product that uses human gene transfer (called hMaxi-K) when it is given to patients with overactive bladder.
- Trial name
- NCT00495053
- Testing
- hMaxi-K
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder, Detrusor, Overactive
TPTNS: Home vs Hospital Treatment for Overactive Bladder
Comparison of home versus hospital Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS). TPTNS has been shown to be an effective treatment of overactive bladder in hospital.
- Trial name
- NCT03727711
- Testing
- TPTNS
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- NHS Greater Glasgow and Clyde
Neurogenic Detrusor Overactivity
BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG
Fesoterodine (Toviaz™) extended-release (ER) tablets are currently manufactured by Aesica Pharmaceuticals, Zwickau, Germany (Zwickau).
- Trial name
- NCT04478357
- Testing
- 4 mg Fesoterodine ER tablet from Zwickau, 4 mg fesoterodine ER tablet from Freiburg, 8 mg fesoterodine ER tablet from Zwickau
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overactive Bladder Syndrome, Detrusor Overactivity
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
About one to two million women in Taiwan suffers from overactive bladder (OAB). The most commonly used anti-muscarinic drugs have a high rate of side effects.
- Trial name
- NCT04693897
- Testing
- Mirabegron 50 MG, Solifenacin Succinate 5 MG
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Parkinson's Disease, Multiple System Atrophy
Botulinum A Toxin in Patients With Parkinson's Disease
The researchers investigated the effectiveness and safety of BoNT/A injected into the detrusor muscle in patients with PD and MSA all of whom had detrusor muscle overactivity unresponsive to conventional medical therapy.
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Detrusor Overactivity
- Trial name
- Botox-PD (NCT00822913)
- Testing
- Intravesical injection of Botulinum A toxin
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Of Perugia
Detrusor Overacitivity
Comparisons of Phasic and Terminal DO
Overactive bladder is a common issue among women of childbearing age, regardless of their childbirth experience. Some of these women may exhibit detrusor overactivity in urodynamic studies.
- Trial name
- NCT06793046
- Where
- Taiwan
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Overactive Bladder
Audiovisual Stimulus During Urodynamics
Many women have the need to run to the restroom frequently during the night and day, a condition called "overactive bladder". Embarrassing urinary leakage is also commonly associated with these symptoms.
- Trial name
- AVUDE (NCT02670486)
- Testing
- Audiovisual stimulus
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- Women and Infants Hospital of Rhode Island